|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
on1038495772 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
180602s2018 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d VLY
|d OCLCF
|d DST
|d K6U
|d OCLCQ
|d OCLCO
|d SXB
|
| 019 |
|
|
|a 1162111402
|a 1241753229
|a 1289384388
|a 1300669173
|a 1303323555
|a 1303472946
|
| 020 |
|
|
|a 9781681083674
|
| 020 |
|
|
|a 1681083671
|
| 035 |
|
|
|a (OCoLC)1038495772
|z (OCoLC)1162111402
|z (OCoLC)1241753229
|z (OCoLC)1289384388
|z (OCoLC)1300669173
|z (OCoLC)1303323555
|z (OCoLC)1303472946
|
| 050 |
|
4 |
|a RC636
|b .F766 2018
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Atta-ur-Rahman.
|
| 245 |
1 |
0 |
|a Frontiers in Clinical Drug Research - Hematology.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2018.
|
| 300 |
|
|
|a 1 online resource (272 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Frontiers in Clinical Drug Research - Hematology Ser. ;
|v v. 3
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro; CONTENTS; PREFACE; List of Contributors; Advances in the Understanding and Treatment of Immune Thrombocytopenia; José Perdomo*; INTRODUCTION; Platelet Biogenesis; Platelet Function; Epidemiology, Aetiology and Disease Progression; Platelet Destruction in ITP; Recent Developments; Impairment of Platelet Production in ITP; Disease Characteristics and Therapies; Need for Novel Therapies; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Recent Developments in Chronic Myeloid Leukemia Biology and Treatment.
|
| 505 |
8 |
|
|a Massimiliano Bonifacio1,* and Claudio Sorio2,*INTRODUCTION; PART I: BIOLOGY; Signaling Mechanisms Altered in CML; Oncosuppressors Genes in CML: A Role for Cytosolic and Receptor-like PTPs; Oncogenic PTPs; Non-coding RNAs in CML; Other Tumor Promoting Pathways; Identifying Cancer Stem Cell in CML; Targeting LSCs; PART II: CLINICS; OPTIONS OF FRONT-LINE MANAGEMENT OF CML; Imatinib; Nilotinib; Dasatinib; Bosutinib and Ponatinib; THE SEQUENTIAL USE OF TKI IN SECOND OR FURTHER LINES OF TREATMENT; BCR-ABL Mutations; After Imatinib Failure; After Failure of Nilotinib or Dasatinib.
|
| 505 |
8 |
|
|a Indications for HSCTTHE PROGNOSTIC SIGNIFICANCE OF EARLY MOLECULAR RESPONSE; Imatinib; Nilotinib; Dasatinib; Bosutinib; Absolute vs Relative Reduction of BCR-ABL1 Levels; Therapeutic Strategies Based on EMR; DEEP MOLECULAR RESPONSE AND DISCONTINUATION OF TREATMENT; Discontinuation Studies; Predictive Factors of DMR; The Impact of DMR on Survival; PREDICTING RESPONSE TO TKI; Risk Score Systems; Age; Comorbidities; Gender; Cytogenetic at Diagnosis; Transcript Type; Mutations; Predicting Response to 2G TKI After Imatinib Failure; New and Alternative Biomarkers of Response to Treatment.
|
| 505 |
8 |
|
|a CONCLUDING REMARKSABBREVIATIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Role of Immunomodulatory Drugs in the Treatment of Lymphoid and Myeloid Malignancies; Ota Fuchs*; INTRODUCTION; CRL4CRBN as a Part of Ubiquitin-Proteasome System; Regulation of CRBN-Associated Proteins in Multiple Myeloma by Lenalidomide; Biomarker of Response or Resistance to Lenalidomide and Pomalidomide; Therapy for Multiple Myeloma Patients with Low CRBN Expression; Importance of CRBN for Immunomodulatory Drugs Activity in Lymphoid Malignancies.
|
| 505 |
8 |
|
|a CLINICAL STUDIES IN LYMPHOID MALIGNANCIESRelapsed/ Refractory CLL; B-Cell NHL; Multiple Myeloma; CLINICAL STUDIES IN MYELOID MALIGNANCIES; Myelodysplastic Syndrome; Randomized Phase III Placebo-Controlled Study of Lenalidomide in del(5q) Patients; Further Clinical Studies of Lower Risk MDS Patients with del(5q) Treated with Lenalidomide; Treatment of del(5q) Patients with Relapse during Lenalidomide Exposure; Therapy with Lenalidomide in Combination with Another Drug in MDS; Mechanisms of Action of Lenalidomide.
|
| 500 |
|
|
|a Role of Cereblon in the Efficacy of Lenalidomide in del(5q) MDS and non-del(5q) MDS.
|
| 650 |
|
0 |
|a Blood
|x Diseases.
|
| 650 |
|
0 |
|a Hematology.
|
| 650 |
|
7 |
|a Blood
|x Diseases
|2 fast
|
| 650 |
|
7 |
|a Hematology
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Frontiers in Clinical Drug Research - Hematology.
|d Sharjah : Bentham Science Publishers, ©2018
|z 9781681083681
|
| 830 |
|
0 |
|a Frontiers in Clinical Drug Research - Hematology Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=5392646
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|